Doravirine, also known as MK-1439, is a non-nucleoside reverse transcriptase inhibitor under development by Merck & Co. for use in the treatment of HIV/AIDS. MK-1439 is a novel NNRTI with a 50% inhibitory concentration (IC50) of 12, 9.7, and 9.7 nM against the wild type (WT) and K103N and Y181C reverse transcriptase (RT) mutants, respectively. MK-1439 showed excellent potency in suppressing the replication of WT virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC95 of 43, 27, and 55 nM, respectively. MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).
Gauthier, Donald R., Jr.; Sherry, Benjamin D.; Cao, Yang; Journet, Michel; Humphrey, Guy; Itoh, Tetsuji; Mangion, Ian; Tschaen, David M. Highly Efficient Synthesis of HIV NNRTI Doravirine. Organic Letters. Volume 17. Issue 6. Pages 1353-1356. Journal; Online Computer File. (2015).
Zhang, Li-Kang; Yang, Ross; Sheng, Huaming; Helmy, Roy; Zheng, Jinjian; Cao, Yang; Gauthier, Donald R. Jr. Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis. Journal of Mass Spectrometry. Volume 51. Issue 10. Pages 959-968. Journal; Online Computer File. (2016).
Campeau, Louis-Charles; Chen, Qinghao; Gauvreau, Danny; Girardin, Melina; Belyk, Kevin; Maligres, Peter; Zhou, Guoyue; Gu, Chaozhan; Zhang, Wei; Tan, Lushi; O'Shea, Paul D. A Robust Kilo-Scale Synthesis of Doravirine. Organic Process Research & Development. Volume 20. Issue 8. Pages 1476-1481. Journal; Online Computer File. (2016).
Cao, Yang; Gauthier, Donald R., Jr.; Humphrey, Guy R.; Itoh, Tetsuji; Journet, Michel; Qian, Gang; Sherry, Benjamin D.; Tschaen, David M. Process for preparing pyridin-2(1H)-one derivatives as reverse transcriptase inhibitors. Assignee Merck Sharp & Dohme Corp., USA. WO 2015084763. (2015).
Itoh, Tetsuji; Jeon, Ingyu; Mangion, Ian; Qian, Gang; Sherry, Benjamin D.; Gauthier, Donald R.; Cao, Yang. A process for the preparation of phenoxyoxodihydrotriazolylmethylpyridinone derivatives. Assignee Merck Sharp & Dohme Corp., USA. WO 2014089140. (2015).
